BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28489582)

  • 1. Association between the ERCC2 Asp312Asn polymorphism and risk of cancer.
    Xiao F; Pu J; Wen Q; Huang Q; Zhang Q; Huang B; Huang S; Lan A; Zhang Y; Li J; Zhao D; Shen J; Wu H; He Y; Li H; Yang X
    Oncotarget; 2017 Jul; 8(29):48488-48506. PubMed ID: 28489582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms of xeroderma pigmentosum group D gene Asp312Asn and Lys751Gln and susceptibility to prostate cancer: a systematic review and meta-analysis.
    Ma Q; Qi C; Tie C; Guo Z
    Gene; 2013 Nov; 530(2):309-14. PubMed ID: 23973729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive assessment of associations between ERCC2 Lys751Gln/Asp312Asn polymorphisms and risk of non- Hodgkin lymphoma.
    Zhou JY; He LW; Liu J; Yu HL; Wei M; Ma WL; Shi R
    Asian Pac J Cancer Prev; 2014; 15(21):9347-53. PubMed ID: 25422223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.
    Wen F; Zhao Z; Liu C; Yin Q; Weng J; Wang Y; Ma Y
    Tumour Biol; 2014 Apr; 35(4):2959-65. PubMed ID: 24234258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of XPD/ERCC2 polymorphisms on gastric cancer risk among different ethnicities: a systematic review and meta-analysis.
    Xue H; Lu Y; Lin B; Chen J; Tang F; Huang G
    PLoS One; 2012; 7(9):e43431. PubMed ID: 23028453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis.
    Wu Y; Yang Y
    Tumour Biol; 2014 Jun; 35(6):5245-57. PubMed ID: 24504678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms of xeroderma pigmentosum group D and prostate cancer risk: a meta-analysis.
    Zhu H; Cao S; Liu Y; Ding X; Wu Q; Ma H
    J Cancer Res Ther; 2013; 9(2):187-92. PubMed ID: 23771356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
    Zhou X; Zeng Y; Jiang H; Xia L; Liu C
    Melanoma Res; 2018 Aug; 28(4):311-318. PubMed ID: 29768284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A haplotype encompassing the variant allele of DNA repair gene polymorphism ERCC2/XPD Lys751Gln but not the variant allele of Asp312Asn is associated with risk of lung cancer in a northeastern Chinese population.
    Yin J; Vogel U; Ma Y; Qi R; Sun Z; Wang H
    Cancer Genet Cytogenet; 2007 May; 175(1):47-51. PubMed ID: 17498557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between the ERCC2 rs13181 polymorphism and the risk of glioma: a meta-analysis.
    Jia TL; Wu HJ; Wang HB; Ma WB; Xing B
    Genet Mol Res; 2015 Oct; 14(4):12577-84. PubMed ID: 26505408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xeroderma pigmentosum group D polymorphisms and esophageal cancer susceptibility: a meta-analysis based on case-control studies.
    Yang R; Zhang C; Malik A; Shen ZD; Hu J; Wu YH
    World J Gastroenterol; 2014 Nov; 20(44):16765-73. PubMed ID: 25469049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene with the risk of non-Hodgkin's lymphoma: evidence from a meta-analysis.
    Chen S; Zhu JH; Wang F; Huang SY; Xue WQ; Cui Z; He J; Jia WH
    Chin J Cancer; 2015 Mar; 34(3):108-14. PubMed ID: 25962431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphism of ERCC2 Asp312Asn with lung cancer risk: evidence from 20,101 subjects.
    Tan X; Wang Y; Shi L; Xian L; Guo J; Liang G; Chen M
    Genet Test Mol Biomarkers; 2014 Jan; 18(1):50-6. PubMed ID: 24083550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of two ERCC2 (XPD) polymorphisms, Asp312Asn and Lys751Gln, in breast cancer.
    Pabalan N; Francisco-Pabalan O; Sung L; Jarjanazi H; Ozcelik H
    Breast Cancer Res Treat; 2010 Nov; 124(2):531-41. PubMed ID: 20379847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between ERCC2 Asp312Asn polymorphism and breast cancer risk: a meta-analysis involving 22,766 subjects.
    Yao L; Qiu LX; Yu L; Yang Z; Yu XJ; Zhong Y; Hu XC; Yu L
    Breast Cancer Res Treat; 2010 Aug; 123(1):227-31. PubMed ID: 20127278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of association between XPD Lys751Gln and Asp312Asn polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies.
    Zhang Y; Ding D; Wang X; Zhu Z; Huang M; He X
    Int J Colorectal Dis; 2011 Oct; 26(10):1257-64. PubMed ID: 21541661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC2 Lys751Gln and Asp312Asn polymorphisms and gastric cancer risk: a meta-analysis.
    Chen B; Zhou Y; Yang P; Wu XT
    J Cancer Res Clin Oncol; 2011 Jun; 137(6):939-46. PubMed ID: 20981556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of ERCC2 Gene Polymorphisms with Susceptibility to Diffuse Large B-Cell Lymphoma.
    Tong Y; Xiang Y; Li B; Bao S; Zhou Y; Yuan W; Ling Y; Hao D; Zhu H; Sun Z
    Med Sci Monit; 2018 Oct; 24():7015-7022. PubMed ID: 30279407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC2/XPD Lys751Gln and Asp312Asn gene polymorphism and lung cancer risk: a meta-analysis involving 22 case-control studies.
    Zhan P; Wang Q; Wei SZ; Wang J; Qian Q; Yu LK; Song Y
    J Thorac Oncol; 2010 Sep; 5(9):1337-45. PubMed ID: 20651612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.
    Yan Y; Liang H; Light M; Li T; Deng Y; Li M; Li S; Qin X
    Tumour Biol; 2014 Mar; 35(3):1907-15. PubMed ID: 24101192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.